Up to 60% off Profit Pro - Limited Time Offer!
Winter Sale

60% off Profit Pro - Limited Time Offer!

Ak

Akero Therapeutics Inc

AKRO · NASDAQ
AKRO · NASDAQ

Next Earnings: 26 Feb 2025

28.10
USD-0.20-0.71%

Latest News

    coinpedia

    Crypto News Today (Dec 18, 2024): Binance Announces Delisting of WRX, AKRO, and BLZ

      CoinOtag

      Binance Plans to Delist AKRO, BLZ, and WRX Trading Pairs, Potentially Triggering Further Price Volatility

        coinpedia

        Breaking News: WazirX Coin to Be Delisted From Binance Along With AKRO and BLZ

        Analysts Recommendations

        Bullish

        Buy

        Strong Buy

        Buy

        Hold

        Sell

        Strong Sell

        Day Range

        28.02USD
        28.79USD

        52 Week Range

        15.32USD
        37.00USD

        Market Cap

        1.99BUSD

        lock-imagelock-image

        Get Full Access with Profit PRO

        See which Billionaires own this investment

        About

        General Information

        Type

        Common Stock

        Exchange

        NASDAQ

        Currency Code

        USD

        Currency Name

        US Dollar

        Country Name

        USA

        Country ISO

        US

        ISIN

        US00973Y1082

        CUSIP

        00973Y108

        Sector

        Healthcare

        Industry

        Biotechnology

        Fiscal Year End

        December

        IPO date

        -

        Updated At

        -

        Highlights

        PE Ratio

        -

        PEG Ratio

        -

        Book Value

        10.61

        Dividend Share

        -

        Dividend Yield

        -

        Earnings Share

        -3.78

        Wall Street Target Price

        48.2727

        EPS Estimate Current Year

        -3.9703

        EPS Estimate Next Year

        -4.8687

        EPS Estimate Current Quarter

        -0.9

        EPS Estimate Next Quarter

        -0.95

        Most Recent Quarter

        -

        Profitability

        Revenue TTM

        0

        Gross Profit TTM

        0

        EBITDA

        -269,265,984

        Profit Margin

        0.00%

        Return On Assets TTM

        -23.17%

        Return On Equity TTM

        -35.90%

        Revenue Per Share TTM

        0

        Qtly Revenue Growth YOY

        0.00%

        Diluted Eps TTM

        -3.78

        Qtly Earnings Growth YOY

        0.00%

        Valuation

        Trailing PE

        0.00

        Forward PE

        0

        Price Sales TTM

        0

        Price Book MRQ

        2.7

        Enterprise Value Revenue

        0

        Enterprise Value EBITDA

        -6

        Peers analysis

        • CSL Ltd
          CSLLYCSL Ltd

          88.70

          1.04%
        • BioNTech SE
          BNTXBioNTech SE

          113.91

          0.41%
        • Vertex Pharmaceuticals Inc
          VRTXVertex Pharmaceuticals Inc

          408.14

          0.05%
        • argenx SE
          ARGNFargenx SE

          630.00

          0.00%
        • CSL Limited
          CMXHFCSL Limited

          173.50

          0.00%
        • Regeneron Pharmaceuticals Inc
          REGNRegeneron Pharmaceuticals Inc

          714.47

          0.00%
        • UCB SA
          UCBJFUCB SA

          198.28

          0.00%
        • UCB SA ADR
          UCBJYUCB SA ADR

          99.02

          -0.96%
        • Alnylam Pharmaceuticals Inc
          ALNYAlnylam Pharmaceuticals Inc

          242.01

          -0.60%
        • argenx NV ADR
          ARGXargenx NV ADR

          629.00

          -0.16%